Montebello Diagnostics AS
Score · fiscal year 2024
73of 100
How to read this: the company is ahead of 88 % of companies in the Morning class Medium in the same sector in 2024. What does this mean?
Rank in the Morning class Medium: 406 of 3,514 · What are Morning company classes?
Place in the whole sector: 2,493 of 22,221 · Handel
Profile
Lion · Leader
High profitability, high solidity
Position against comparable companies in 2024, not a verdict on the company. Based on profitability 94 and solidity 51 out of 100 among companies in the Morning class Medium in the same sector in 2024. Methodology
Against the sector
Montebello Diagnostics AS is 23 points above the median for companies in the Morning class Medium in the same sector in 2024.
Median score 50 among 3,514 companies.
Against companies in the Morning class Medium in the same sector in 2024: operating margin 16.6% (median 2.9%) and equity ratio 31.2% (median 30.2%).
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 232 MNOK | 92 MNOK |
| Operating margin | 16.6% | 2.9% |
| Profit margin | 17.2% | 2.7% |
| Return on assets | 36.3% | 11.8% |
| Equity ratio | 31.2% | 30.2% |
| Debt-to-equity | 2.21 | 2.23 |
| Current ratio | 1.41 | 1.40 |
| Revenue growth | 58.5% | 5.1% |
| Revenue per employee | 28.96 MNOK | 4.92 MNOK |
The median and “ahead of” refer to companies in the Morning class Medium in the same sector in 2024. The bar shows the share of companies the figure is ahead of.
With an index of 73, Montebello Diagnostics AS does better than 88% of companies in the Morning class Medium in the same sector (3,514 companies) in 2024.
Score 2023–2025
- Montebello Diagnostics AS
- Median: companies in the Morning class Medium in the same sector
What the numbers say
Montebello Diagnostics AS had an operating margin of 16.6% and an equity ratio of 31.2% in 2024, and ranks 2,493 of 22,221 in Handel.
From 2023 to 2024: revenue grew by 59% and the operating margin rose from 8.0% to 16.6%.
This text is generated automatically from the 2024 accounts.
Three simple methods
The methods give between 34 MNOK and 342 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 10.0 | 314 MNOK |
| EV/EBIT | 8.0 | 342 MNOK |
| P/B | 1.0 | 34 MNOK |
A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation
Worth a closer look
No rules were triggered for this year.
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Financial costs were 0.3% of the debt in 2024. The policy rate averaged 4.50 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.
See interest rates, prices and exchange rates for the sector
Data quality
No anomalies found in the figures.
Scenario analysis: the sector's weakest year
We have no accounts for 2022, the sector's weakest year, for this company.
The sector's weakest year was 2022, with a median operating margin of 1.5%. Based on the 11 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 94 | weight 30% |
|---|---|---|
| Solidity | 51 | weight 25% |
| Liquidity | 51 | weight 15% |
| Growth | 95 | weight 15% |
| Consistency | 65 | weight 15% |
Durability: 64 (average over 2 years)
Index version 2. Data completeness 100%: the share of the weights that had data.
Questions and answers
How profitable is Montebello Diagnostics AS?
The operating margin was 16.6% in 2024, against a median of 2.9% among companies in the Morning class Medium in the same sector. Return on assets was 36.3%.
How solid is Montebello Diagnostics AS?
The equity ratio was 31.2% in 2024 (median 30.2%). Debt-to-equity was 2.21 (median 2.23).
What is the liquidity of Montebello Diagnostics AS like?
The current ratio was 1.41 in 2024 (median 1.40).
How does Montebello Diagnostics AS compare in Handel?
Montebello Diagnostics AS ranks 2,493 of 22,221 in Handel for 2024. Among companies in the Morning class Medium it is number 406 of 3,514. Revenue changed by 58.5% from the year before.
Public contracts
- Contracts awarded since 2024
- 9
- in 8 notices (lots counted separately)
- Total awarded value since 2024
- 0.8 MNOK
- 4 contracts without a stated value are not in the total.
- Framework agreements
- 4
- Left out of the total: the value is a ceiling, not actual spend.
Based on notices in Doffin. Does not show call-offs under framework agreements or purchases below the publication threshold. Values are as stated by the buyer.
Source: Doffin (DFØ), fetched 28 October 2026. Winners are matched on organisation number.
Contains data under the Norwegian licence for public data (NLOD 2.0) made available by Doffin/the Norwegian Agency for Public and Financial Management (DFØ). NLOD 2.0
From the Central Coordinating Register
- Org. no.
- 994171127
- Legal form
- AS
- Sector
- Handel (46.460)
- Morning company class
- Medium
- Employees
- 8 registered 10 April 2026
- Founded
- 28 April 2009 17 years in operation
- Share capital
- 0.10 MNOK
- Business address
- 3. etg, Ole Deviks vei 16, 0666 OSLO
- Municipality
- Oslo rank 63–220 of 357 in Norway
- Latest accounts filed
- 2025
- Website
- www.montebello.no
- LEI
- 635400FNJEIVNILUBU13 renews 3 March 2021
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
Loading roles …
Source: Central Coordinating Register, fetched 29 October 2026. Only names are shown.
- Parent company
- No parent company: owned by persons
Source: GLEIF (Global Legal Entity Identifier Foundation), fetched 30 October 2026. The parent is the one the company itself reported to GLEIF.
Owners and shareholdings will appear here once the shareholder data extract is in place.
Coming · not built yet
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Figures last fetched 29 October 2026.
Year by year · 2023–2025
| Key figure | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Index | 55 | 73 | 60 | |
| Rank | 8,867 | 2,493 | 6,935 | |
| Operating margin | 8.0% | 16.6% | 17.0% | |
| Return on assets | 16.3% | 36.3% | 36.0% | |
| Equity ratio | 24.9% | 31.2% | 31.4% | |
| Current ratio | 1.26 | 1.41 | 1.42 | |
| Revenue growth | – | 58.5% | −0.8% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating revenue | 146.1 MNOK | 231.7 MNOK | 229.9 MNOK |
| Operating profit | 11.7 MNOK | 38.4 MNOK | 39.1 MNOK |
| Profit before tax | 10.5 MNOK | 39.9 MNOK | 39.2 MNOK |
| Net profit | 7.9 MNOK | 31.4 MNOK | 30.5 MNOK |
| Financial expenses | 1.4 MNOK | 0.2 MNOK | 0.3 MNOK |
| Total assets | 72.8 MNOK | 110.6 MNOK | 109.7 MNOK |
| Current assets | 68.6 MNOK | 107.3 MNOK | 107.0 MNOK |
| Equity | 18.1 MNOK | 34.5 MNOK | 34.5 MNOK |
| Retained earnings | 17.3 MNOK | 28.7 MNOK | 28.7 MNOK |
| Total liabilities | 54.7 MNOK | 76.1 MNOK | 75.2 MNOK |
| Current liabilities | 54.7 MNOK | 76.1 MNOK | 75.2 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 29 October 2026, accounts id 5784939.
Further
Similar companies
- Hero Norway AS index 73, rank 2,480 · compare
- Saltex AS index 73, rank 2,487 · compare
- Lars Kroken AS index 73, rank 2,490 · compare
- Automotor AS index 73, rank 2,510 · compare
- Monsieur Scabal AS index 73, rank 2,511 · compare